靶向Engrailed-1成纤维细胞治疗特发性声门下狭窄
研究比较iSGS患者病变声门下与远端健康气管中EN1表达,并用verteporfin处理iSGS成纤维细胞。发现病变处EN1表达升高,verteporfin体外降低COL1A1、COL3A1、EN1及YAP/TAZ通路基因表达,提示靶向EN1成纤维细胞可能减少iSGS纤维化。
要点
- iSGS病变声门下EN1表达显著升高。
- verteporfin体外降低iSGS成纤维细胞纤维化基因表达。
- 靶向YAP/TAZ-EN1轴可能成为iSGS治疗方向。
核心结论
- EN1及相关YAP/TAZ信号通路在iSGS中升高。
- verteporfin体外抑制YAP/TAZ并减弱EN1和COL1A1表达。
- 靶向EN1表达成纤维细胞是减少iSGS纤维化的潜在治疗靶点。
研究设计与样本
- 研究纳入iSGS患者(n=6)的病变声门下和远端健康气管活检组织。
- 采用qRT-PCR、单细胞RNA测序数据分析、流式细胞术和免疫组化比较EN1表达。
- 对病变iSGS组织来源成纤维细胞进行verteporfin(5 μM)或对照处理,分析基因和蛋白表达。
主要发现
- iSGS声门下EN1表达较对照增加(倍数变化=58.86,SD=65.12,p=0.031)。
- 免疫组化显示病变iSGS声门下EN1密集表达。
- verteporfin处理使COL1A1基因表达降低81.75%(SD=9.28,p=0.031)。
- verteporfin处理使COL3A1基因表达降低22.77%(SD=17.11,p=0.031)。
- verteporfin处理使EN1表达降低26.32%(SD=28.25,p=0.031),并降低YAP/TAZ相关基因AMOTL2、CCN1、CCN2、YAP1和WWTR1。
临床怎么用
- YAP/TAZ-EN1信号轴可作为iSGS抗纤维化治疗的潜在干预靶点。
局限性
- 证据水平为N/A。
- 研究样本量小(n=6)。
- verteporfin效果为体外实验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Idiopathic subglottic stenosis (iSGS) is characterized by pathologic deposition of extracellular matrix (ECM) secondary to dysregulated fibroblasts. Engrailed-1 expressing fibroblasts have been shown to promote ECM deposition in fibrosis. Verteporfin has been shown to reduce EN1 expression in fibroblasts through YAP/TAZ signaling. However, EN1 expression, YAP/TAZ signaling, and verteporfin treatment have not been investigated in iSGS pathogenesis. METHODS: Biopsies of diseased subglottis and distal healthy trachea of iSGS patients (n = 6) were assessed. qRT-PCR, analysis of iSGS single-cell RNA sequencing data, flow cytometry and immunochemistry were used to compare the expression of EN1. Fibroblasts from diseased iSGS tissue were treated with verteporfin (5 μM) or control and gene and protein expression analysis was performed for EN1, YAP/TAZ pathway and fibrotic genes. RESULTS: The iSGS subglottis demonstrated increased expression of EN1 (fold change = 58.86, SD = 65.12, p: 0.031) compared to controls. Immunohistochemistry analysis of the diseased iSGS subglottis showed that EN1 was densely expressed. Verteporfin treatment of iSGS fibroblasts in vitro led to an 81.75% (SD = 9.28, p: 0.031) reduction in COL1A1 and 22.77% (SD = 17.11, p: 0.031) reduction in COL3A1 gene expression. This was associated with a 26.32% (SD = 28.25, p: 0.031) reduction in EN1 expression and reductions in the YAP/TAZ associated genes AMOTL2, CCN1, CCN2, YAP1, and WWTR1. CONCLUSION: EN1 and the associated YAP/TAZ signaling pathway are increased in iSGS. Verteporfin treatment inhibited YAP/TAZ expression and attenuated EN1 and COL1A1 expression in vitro. Targeting EN1 expressing fibroblasts through inhibition of YAP/TAZ signaling represents a potential therapeutic target to reduce fibrosis in iSGS. LEVEL OF EVIDENCE: N/A.
引用
- Saeedi, Collins, Lopez-Fay, et al. Targeting Engrailed-1 Fibroblasts in Idiopathic Subglottic Stenosis. Laryngoscope. 2026. PMID: 42947382. doi:10.1002/lary.71012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。